NAS10028,385−3.46%S&P7,580−1.82%GOLD$3,904+0.13%BTC$78,261+0.02%VIX19.09−1.70%latest tape · as of 08:40 UTC
The Screen · Technology · Semiconductors
Texas Instruments
TXN · a US exchange · USD · Market cap $286.1B · 33,000 employees
Texas Instruments Incorporated designs, manufactures, and sells semiconductors to electronics designers and manufacturers in the United States, China, the rest of Asia, Europe, the Middle East, Africa, Japan, and internationally.
FAIL · Does not pass the screen
300.84 USD
Price as of 30 Oct 2026Daily close, not a live quote
Screened 2026-10-30 · the tape above runs as of 08:40 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Positioning political selling, disclosed 2026-10-14
Options put/call open interest 0.28, read 2026-11-01
Ethical does not pass the values gate
Price300.84 USD
Fair value218.68
Ethical score10.0/100
RatingAVOID
Our investment reviews on this name
2026-10-02Read Accumulation278.07+8.2% to today ✓Distribution gives way to Accumulation with volume flow in agreement
2026-08-23Read Distribution265.60+13.3% to today Markup gives way to Distribution after a 7% slide in 7 weeks
2026-07-02Read Markup285.06+5.5% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Texas Instruments holds its Markup at $300.84. The statistical read favours the sellers, held for 75 days.
As held on the ledger · 2026-10-30
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 75 days
Price at the screen
$300.84
Valuation
40.59 trailing · 27.16 forward price to earnings
Values screen
FAIL· score 10.0
Beta
1.34
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
40.62%
Below 33%
Interest-bearing debt is 40.6% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
4.79%
Below 33%
Cash held in interest-bearing accounts and securities is 4.8% of assets, under the one-third limit.
Pass
Receivables
15.00%
Below 49%
Money owed to the company is 15.0% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Texas Instruments's business is in a permissible area, but its interest-bearing debt is about 41% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-01. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when TXN's ethical verdict changes
Today TXN does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The quantitative screen above is arithmetic. Separately, community boycott lists cite this company: Cited by BDS movement for operating semiconductor R&D and manufacturing facilities in Israel. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads AVOID: it trades above our $218.68 fair value estimate, strong competitive moat, 27.70% revenue growth.
Fair value range in USD, drawn from the 2026-10-30 screen. The gold marker is the market price at the same screen. The price runs 27.3% above the base estimate.
Third-party analyst targets: 29 covering, consensus Buy. The average target sits +13% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $218.68, with a range of $218.68 to $251.49, dated to the 2026-10-30 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Texas Instruments: Failing the Ethical Gauge in a Cyclical Storm
Imagine electronics designers worldwide racing to create the next gadget, and Texas Instruments is their go-to for semiconductors. The company operates in a highly cyclical industry, experiencing robust revenue growth of 23%, with a profit margin of 31% and a robust return on equity rating of 35%, highlighting its strong competitive moat. However, the market's optimism has the stock priced at a substantial 19% premium over our fair value estimate, which is a red flag in a cyclical industry.
The cyclical nature of the semiconductor industry poses a special risk. Currently, the company's valuation is high, which is typically a warning sign rather than a bargain, especially during peak earnings periods in such industries. A low multiple following a period of high earnings could indicate a cyclical value trap.
Unfortunately, despite its strong financial performance, Texas Instruments fails our ethical screen due to a concerning debt ratio. This is a critical factor in our evaluation process, as sustainable practices are as important as financial success. The consensus rating from analysts is a 'buy' with a median target price of $340, yet it's essential to consider not just the potential returns but the ethical standards of an investment.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
TXN trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Accumulation$279.12+0.0%Entry 20
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285.
2026-10-21Accumulation$279.12+0.0%Entry 19
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Accumulation$279.12+0.0%Entry 18
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19Accumulation$279.12+0.0%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Accumulation$279.12+0.0%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 63% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-17Accumulation$279.12+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 63% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-16Accumulation$279.12-1.6%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 63% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-15Accumulation$283.74+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 63% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-14Accumulation$283.74+2.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 63% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 63% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 43%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (32 analysts) rates it buy, with a mean price target of $285.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
